Xi Chen

US Patent:

6429312, Aug 6, 2002

Filed:

Mar 19, 2001

Appl. No.:

09/812199

Inventors:

Jun Yuan - Clinton CT
Xi Chen - New Haven CT

Assignee:

Neurogen Corporation - Branford CT

International Classification:

C07D40914

US Classification:

544295, 544363, 544364, 544375, 544376, 544333, 5462811, 546146, 546175, 546194, 546202, 546256, 549 43, 549 48

Abstract:

Disclosed are compounds of the formula: or the pharmaceutically acceptable acid addition salts thereof, wherein: R , R , R , R are the same or different and represent hydrogen, C -C alkyl, halogen, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy, C -C alkoxy, âO CRâ, âNHCORâ, âCORâ, âSO Râ, where Râ is C -C alkyl and wherein m is 0, 1 or 2; or R , R , R , R independently represent âCONRâRâ, or âNRâRâ where Râ and Râ independently represent hydrogen or C -C alkyl; R is hydrogen or C -C alkyl; and R represents an aminoalkyl group, which compounds are useful in the treatment of affective disorders such as schizophrenia, depression, Alzheimers disease, movement disorders such as Parkinsonism and dystonia, and other disorders which respond to dopaminergic blockade such as substance abuse and obsessive compulsive disorders. Further, compounds of this invention may be useful in treating the extrapyramidal side effects associated with the use of conventional neuroleptic agents.

US Patent:

20060100225, May 11, 2006

Filed:

Mar 23, 2005

Appl. No.:

11/088276

Inventors:

Xi Chen - Killingworth CT, US
Andrew Thurkauf - Ridgefield CT, US
Shirley Louise-May - Guilford CT, US

International Classification:

A61K 31/513
A61K 31/505
C07D 239/32

US Classification:

514269000, 514275000, 544320000, 544330000

Abstract:

Compounds of Formula 1, and pharmaceutically acceptable forms thereof, are provided: wherein the variables X, Y, Z, A, R, R, R, Rand Rare defined herein. Certain compounds of Formula 1 described herein which possess potent antiviral activity. Certain compounds of Formula 1 that are potent and/or selective inhibitors of Hepatitis C virus replication. Pharmaceutical compositions containing one or more compounds of Formula 1, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents are also provided. Methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula 1 effective to reduce signs or symptoms of the disease or disorder are disclosed. These infectious diseases include viral infections, particularly HCV infections. Methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound of Formula 1 as a single active agent or administering a compound of Formula 1 in combination with on or more other therapeutic agent.

US Patent:

20100204120, Aug 12, 2010

Filed:

Feb 8, 2010

Appl. No.:

12/702209

Inventors:

Shibo Jiang - Fresh Meadows NY, US
Zhi Qi - Corona NY, US
Xi Chen - Elmhurst NY, US
Chungen Pan - Guangzho, CN

International Classification:

A61K 38/16
C07K 14/00
A61P 31/18

US Classification:

514 12, 530395

Abstract:

Disclosed herein are trimeric polypeptide pharmaceutical compositions comprising three monomers, each monomer comprising a polypeptide having the amino acid sequence of the N-terminal heptad repeat (NHR or HR1) or C-terminal heptad repeat (CHR or HR2) of the transmembrane glycoprotein of human immunodeficiency virus (HIV) and a trimerization motif.

US Patent:

20120319329, Dec 20, 2012

Filed:

Apr 20, 2012

Appl. No.:

13/452441

Inventors:

Xi Chen - New York NY, US

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

B29C 53/02
B29C 59/02

US Classification:

264320, 425352

Abstract:

Self-assembled buckling patterns of thin films on compliant substrates can be used in micro-fabrication. However, most previous work has been limited to planar substrates, and buckling of films on curved substrates has not been widely explored. With the constraining effect from various types of substrate curvature, numerous new types of buckling morphologies can be derived. The morphologies not only enable true three-dimensional (3D) fabrication of microstructures and microdevices, but also can have important implications for the morphogenesis of quite a few natural and biological systems.

US Patent:

57636095, Jun 9, 1998

Filed:

Mar 21, 1996

Appl. No.:

8/619429

Inventors:

Jun Yuan - Clinton CT
Xi Chen - New Haven CT

Assignee:

Neurogen Corporation - Branford CT

International Classification:

C07D40914
C07D40912

US Classification:

544363

Abstract:

Disclosed are compounds of the formula: ##STR1## or the pharmaceutically acceptable acid addition salts thereof, wherein: R. sub. 1, R. sub. 2, R. sub. 3, R. sub. 4 are the same or different and represent hydrogen, C. sub. 1 -C. sub. 6 alkyl, halogen, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy, C. sub. 1 -C. sub. 6 alkoxy, --O. sub. 2 CR', --NHCOR', --COR', --SO. sub. m R', where R' is C. sub. 1 -C. sub. 6 alkyl and wherein m is 0, 1 or 2; or R. sub. 1, R. sub. 2, R. sub. 3, R. sub. 4 independently represent --CONR'R", or --NR'R" where R' and R" independently represent hydrogen or C. sub. 1 -C. sub. 6 alkyl; R. sub. 5 is hydrogen or C. sub. 1 -C. sub. 6 alkyl; and R represents an aminoalkyl group, which compounds are useful in the treatment of affective disorders such as schizophrenia, depression, Alzheimer's disease, movement disorders such as Parkinsonism and dystonia, and other disorders which respond to dopaminergic blockade such as substance abuse and obsessive compulsive disorders. Further, compounds of this invention may be useful in treating the extrapyramidal side effects associated with the use of conventional neuroleptic agents.

US Patent:

57032351, Dec 30, 1997

Filed:

Mar 21, 1996

Appl. No.:

8/619351

Inventors:

Jun Yuan - Clinton CT
Xi Chen - New Haven CT

Assignee:

Neurogen Corporation - Branford CT

International Classification:

C07D40110
C07D29515
C07D21114
C07D21170

US Classification:

544363

Abstract:

Disclosed are compounds of the formula: ##STR1## or the pharmaceutically acceptable acid addition salts thereof, wherein: R. sub. 1, R. sub. 2, R. sub. 3, R. sub. 4, R. sub. 5, R. sub. 6, R. sub. 7, R. sub. 8 and R. sub. 9 are the same or different and represent hydrogen, C. sub. 1 -C. sub. 6 alkyl, halogen, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy, C. sub. 1 -C. sub. 6 alkoxy, --O. sub. 2 CR', --NHCOR', --COR', --SO. sub. m R', where R' is C. sub. 1 -C. sub. 6 alkyl and wherein m is 0, 1 or 2; or R. sub. 1, R. sub. 2, R. sub. 3, R. sub. 4, R. sub. 5, R. sub. 6, R. sub. 7, R. sub. 8 and R. sub. 9 independently represent --CONR'R", or --NR'R" where R' and R" independently represent hydrogen or C. sub. 1 -C. sub. 6 alkyl; R. sub. 10 is hydrogen or C. sub. 1 -C. sub.

US Patent:

60342528, Mar 7, 2000

Filed:

Jun 8, 1999

Appl. No.:

9/328170

Inventors:

Xi Chen - Killingworth CT
Jan W. F. Wasley - Guilford CT

Assignee:

Neurogen Corporation - Branford CT

International Classification:

C07D49504

US Classification:

5483595

Abstract:

Disclosed are compounds of the formula: ##STR1## or the pharmaceutically acceptable salts thereof wherein wherein: R. sub. 1, R. sub. 2, and and R. sub. 4 independenlty represent hydrogen, halogen, alkyl, cyano, alkoxycarbonyl, trifluoromethoxy, SO. sub. 2 NH. sub. 2 or trifluoromethyl; R. sub. 3 represents hydrogen, halogen, alkyl, alkoxy, alkylthio, hydroxy, amino, mono- or di(C. sub. 1 -C. sub. 6)alkylamino, cyano, alkoxycarbonyl, trifluoromethoxy, SO. sub. 2 NH. sub. 2 or trifluoromethyl; or R. sub. 3 represents optionally substituted phenyl; X represents (CH. sub. 2). sub. n where n is an integer; and m is 0 or an integer, which compounds are useful for the treatment and/or prevention of neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depression, anxiety, compulsive behavior, substance abuse, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents.

US Patent:

58832572, Mar 16, 1999

Filed:

Dec 19, 1997

Appl. No.:

8/994588

Inventors:

Jun Yuan - Clinton CT
Xi Chen - New Haven CT

Assignee:

Neurogen Corporation - Branford CT

International Classification:

C07D40112
C07D21170
C07D21114

US Classification:

546203

Abstract:

Disclosed are compounds of the formula: ##STR1## or the pharmaceutically acceptable acid addition salts thereof, wherein: R. sub. 1, R. sub. 2, R. sub. 3, R. sub. 4, R. sub. 5, R. sub. 6, R. sub. 7, R. sub. 8 and R. sub. 9 are the same or different and represent hydrogen, C. sub. 1 -C. sub. 6 alkyl, halogen, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy, C. sub. 1 -C. sub. 6 alkoxy, --O. sub. 2 CR', --NHCOR', --COR', --SO. sub. m R', where R' is C. sub. 1 -C. sub. 6 alkyl and wherein m is 0, 1 or 2; or R. sub. 1, R. sub. 2, R. sub. 3, R. sub. 4, R. sub. 5, R. sub. 6, R. sub. 7, R. sub. 8 and R. sub. 9 independently represent --CONR'R", or --NR'R" where R' and R" independently represent hydrogen or C. sub. 1 -C. sub. 6 alkyl; R. sub. 10 is hydrogen or C. sub. 1 -C. sub.